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Abstract
Background: Chronic subdural hematoma (CSDH) is one of the most frequent reason for cranial neurosurgical
consultation. There is no widely accepted medical treatment for this condition. Herein, we present the protocol for
the Tranexamic Acid (TXA) in Chronic Subdural Hematomas (TRACS) trial aiming at determining whether TXA can
increase the rate of CSDH resolution following conservative management, lower the number of required surgical
procedures and decrease the rate of CSDH recurrence following surgical evacuation.
Methods: TRACS is a multicenter, double-blind, randomized, parallel-design, placebo-controlled, phase IIB study
designed to provide preliminary efficacy data as well as feasibility, safety and incidence data required to plan a
larger definitive phase III trial.
Consecutive patients presenting with a diagnosis of chronic subdural hematoma will be screened for eligibility.
Exclusion criteria include: specific risk factors for thromboembolic disease, anticoagulant use or contraindication to
TXA. A total of 130 patients will be randomized to receive either 750 mg of TXA daily or placebo until complete
radiological resolution of the CSDH or for a maximum of 20 weeks. CSDH volume will be measured on serial
computed tomography (CT) scanning. Cognitive function tests, quality of life questionnaires as well as functional
autonomy assessments will be performed at enrollment, at 10 weeks following randomization and at 3 months
following treatment cessation. During the treatment period, patients will undergo standard CSDH management
with surgery being performed at the discretion of the treating physician. If surgery is performed, the CSDH and its
outer membrane will be sampled for in vitro analysis.
The primary outcome is the rate of CSDH resolution by 20 weeks without intervening unplanned surgical
procedure. Secondary outcomes include: CSDH volume, incidence of surgical evacuation procedures, CSDH
recurrence, cognitive functions, functional autonomy, quality of life, incidence of complications and length of
hospital stay. Planned subgroup analyses will be performed for conservatively versus surgically managed subjects
and highly versus poorly vascularized CSDH.
Discussion: CSDH is a frequent morbidity for which an effective medical treatment has yet to be discovered. The
TRACS trial will be the first prospective study of TXA for CSDH.
Trial registration: NCT ID: NCT02568124.
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Background
Chronic subdural hematoma (CSDH) is one of the most
frequent reasons for cranial neurosurgical consultation
and a significant public health problem. The incidence
in modern series ranges from 13.5 to 58.1 per 100,000
persons, depending on the studied population [1], and it
peaks in the eighth decade.
As the name implies, CSDH results from venous bleeding
in the space between the brain and the dura mater. While a
major trauma is usually required to produce a subdural
bleeding in young adults, a simple fall can be sufficient in
the elderly, because brain atrophy results in stretching of
bridging veins, rendering them susceptible to bleeding from
minor trauma. In the acute stage, hemostasis is achieved
through activation of coagulation cascades and formation
of a blood clot. It is subsequently reorganized and reab-
sorbed following activation of the fibrinolytic cascade. For
unknown reasons, however, this process often fails in the
elderly, where an inflammatory reaction triggers the forma-
tion of a neovascularized membrane surrounding the clot
[2]. It is postulated that activation of fibrinolysis within the
hematoma might sustain a local coagulopathy which would
promote low-volume bleeding from the outer membrane of
the clot [3, 4]. This prevents resolution of the subdural col-
lection, which then becomes “chronic”. Depending on its
size, the hematoma can produce a variety of symptoms ran-
ging from headaches and cognitive dysfunction to seizures,
hemiplegia and coma. In most cases, motor symptoms and
gait disruption will result in subsequent falls, which might
lead to rebleeding [5]. Only 2.4 to 18 % of CSDH will re-
solve spontaneously [6] and most patients will require sur-
gical drainage. In frail, elderly patients, this can be non-
trivial.
There is no widely accepted medical treatment for
CSDH. Evidence is currently available for four classes of
drugs: corticosteroids, angiotensin-converting enzyme
(ACE) inhibitors, platelet-activating factor (PAF) recep-
tor antagonists and antifibrinolytics.
Corticosteroids
Corticosteroids have been proposed as a way to reduce
inflammation and angiogenesis in mild CSDH cases [2].
A recent meta-analysis of CSDHs found 5 studies inves-
tigating corticosteroids as the primary management
strategy and 17 studies assessing its impact as an adju-
vant to surgery [7]. Pooled analysis found no benefit and
an increased morbidity when corticosteroids are used.
Multiple prospective randomized controlled trials are
currently ongoing to clarify the issue (NCT02111785,
NCT02192320, NCT01380028).
ACE inhibitors
In 2007, a retrospective analysis of 438 patients who
underwent surgery for CSDH suggested that concomitant
use of an ACE inhibitor for the management of hyperten-
sion lowered the risk of CSDH recurrence following sur-
gery [8]. Indeed, ACE inhibitors have known
antiangiogenic properties and might inhibit neovasculari-
zation in the CSDH outer membrane. A prospective ran-
domized controlled trial comparing the effect of
perindopril on postoperative recurrence has just been
completed and is pending publication (NCT00915928).
Platelet-activating factor receptor antagonist
Platelet-activating factor has been shown to be a po-
tent lipid mediator of the inflammation involved in
the formation and growth of the CSDH membrane
[9]. Two small prospective studies from a single
group demonstrated that treatment with the PAF re-
ceptor antagonist etizolam decreases the need for sur-
gery [10] and decreases CSDH recurrence after
surgery [11]. No further study is currently announced
despite these interesting results.
Antifibrinolytics
Tranexamic acid (TXA) is an antifibrinolytic agent used
to minimize bleeding in trauma patients [12], high-risk
surgical procedures [13] and refractory menorrhagia
[14]. Its use in the treatment of CSDH was reported in
two papers. The first is a case report of a hemodialyzed
patient with CSDH refractory to three surgical evacua-
tions [15]. The patient was given TXA (20 mg/kg/48 h
intravenously (IV) for 4 weeks, followed by 10 mg/kg/
48 h per os (PO) for 4 weeks) which led to complete
radiological resolution of the CSDH. The patient
remained recurrence-free at the 1-year follow-up. The
second paper is a Japanese case series of 21 consecutive
patients treated with TXA (750 mg PO daily) until radio-
logical CSDH resolution on follow-up computed tomog-
raphy (CT) scans performed every 3 weeks [16]. The
authors report a 100 % success rate with a median treat-
ment duration of 58 days (range 28–137 days).
While these anecdotal reports suggest a role for TXA
in the medical management of CSDH, no interventional
trial on the matter has been published. As of 14 Novem-
ber 2014, a search of the International Committee of
Medical Journal Editors (ICMJE)-approved trial data-
bases (including, “ClinicalTrials.gov,” “ISRCTN.org,”
“anzctr.org.au,” “umin.ac.jp/ctr/index/htm,” “trialregis-
ter.nl” and “eudract.ema.europa.eu”), the World Health
Organization (WHO) International Clinical Trials Regis-
try Platform and PubMed yielded no planned or ongoing
trial of TXA in CSDH. Because of the strong patho-
physiological rationale for the use of TXA in CSDH and
the encouraging reports previously published, we believe
that further investigation of the matter is indicated.
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Objective
We will be conducting a phase IIB trial, called “Tranex-
amic Acid in Chronic Subdural Hematomas” (TRACS),
to investigate whether TXA can increase the rate of
CSDH resolution following conservative management,
lower the number of required surgical procedures and
decrease the rate of CSDH recurrence following surgical
evacuation. The TRACS trial will provide preliminary ef-
ficacy data as well as the safety and incidence data re-
quired to plan a larger definitive phase III trial. The trial
registration ID is NCT02568124. This paper is a sum-
mary of the study protocol adhering to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) Statement [17] (Additional file 1). The




TRACS is a double-blinded, randomized, parallel-design,
placebo-controlled trial investigating the effect of long-
term (up to 20 weeks) TXA administration on CSDH
resolution when used as an adjunct to standard manage-
ment. A total of 130 adult CSDH patients will be ran-
domized to receive either TXA or placebo. Hematoma
resolution will be assessed by serial CT scanning.
Inclusion criteria
TRACS will be open to adult patients (18 years of age or
older) for whom a recent (up to 14 days) CT scan dem-
onstrates the existence of a subdural hematoma contain-
ing a chronic component.
 A subdural hematoma is defined as a measurable
liquid and hemorrhagic collection within the
subdural space as assessed by CT scanning
 A chronic component is defined as a hypodense
(<25 Hounsfield units (HU)) or isodense (25–35
HU) region within the subdural collection in the
absence of anemia or coagulopathy
 In the presence of anemia or coagulopathy, at least
one additional sign suggestive of a chronic process
must be seen. Acceptable signs include:
○ Bilateral hematomas
○ Loculation within the hematoma
○ Visible membrane surrounding the hematoma
Subjects presenting with an acute rebleeding within a
CSDH are eligible.
Exclusion criteria
Patients will be excluded from the study in the fol-
lowing cases:
 Acute subdural hematoma with no chronic
component
 Active thrombotic, thromboembolic or
atheroembolic disease, including:
○ Deep venous thrombosis within the last
6 months
○ Cerebral thrombosis within the last 6 months
○ Symptomatic carotid stenosis that did not
undergo surgery
○ Stroke (ischemic or hemorrhagic) within the last
year
○ Acute coronary syndrome within the last year;
 Past history of unprovoked deep venous thrombosis
or idiopathic pulmonary embolism
 Known hereditary thrombophilia including:
○ Factor V Leiden
○ Antithrombin III mutation
○ Protein C deficiency
○ Protein S deficiency
 Atrial fibrillation (unless under successful rhythm
control therapy)
 Metallic heart valve
 Vascular stenting procedure within the last year
 Cardiac or vascular surgical procedure within the




 Ongoing investigation for suspected malignancy
 Confirmed active malignancy
 Concomitant hormone therapy for malignancy
 Concomitant use of a hormone contraceptive pill
 Macroscopic hematuria
 Known or suspected TXA allergy
 Pregnancy or breastfeeding
 Concomitant use of anticoagulant medication
 Any concern from the attending physician
These extensive exclusion criteria have been selected
to provide maximum safety for the study subjects. It is
likely that our patient population will be significantly
older and at higher risk for thromboembolic complica-
tions than in most other studies of TXA, notably the
trauma studies [12]. Until the effectiveness of TXA use
in CSDH is demonstrated, we believe that any risk factor
for thrombotic events should be carefully considered.
Should any exclusion criteria be newly diagnosed during
the course of the study, treatment will be discontinued,
although follow-up will proceed as planned.
Setting and screening
TRACS is a Canadian multicenter trial. The coordinat-
ing center is the Centre Hospitalier Universitaire de
Sherbrooke (CHUS). Enrollment will take place at the
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CHUS and at the Centre Hospitalier Affilié Universitaire
de Québec. In both centers, all consecutive patients pre-
senting to the neurosurgery department with a diagnosis
of a subdural hematoma with a chronic component will
be screened for eligibility by the treating physicians. It is
likely that some eligible patients will be missed because
of physician oversight. However, this screening method
was deemed more sensitive than a systematic review of
the participating centers’ daily head CT reports, because
a significant proportion of patients are referred for con-
sultation based on head CT scans performed in outside
community hospitals. A screening log will be kept. Fol-
lowing screening, interested and potentially eligible pa-
tients will meet a trained research nurse who will
consent and enroll the subjects.
Power calculation
The primary goal of TRACS is to generate the feasibility,
safety and incidence data required to inform the design
of a larger definitive phase III trial. Powering for efficacy
is, therefore, not required. However, given the impressive
effect size reported in the case series, demonstration of
efficacy might be achievable even within this smaller
phase II study.
At our institution (CHUS) between 2009 and 2012, ad-
ministrative data suggests that about 30 % of CSDH
were symptomatic and underwent surgical treatment.
This amounted to about 28 surgical procedures per-
formed annually when including reoperations (unpub-
lished data). In the literature, rates of complete
radiological resolution following surgery have been re-
ported to be between 70 and 95 % [18] with only 3–
18 % of cases resolving spontaneously if conservative
management is undertaken [6]. Using these data, if we
postulate that 30 % of patients enrolled in the study will
undergo surgical evacuation, the primary outcome in the
placebo group should be met in 23–41 %. We believe
that the effect of TXA would be clinically significant if it
can double the rate of CSDH resolution. Given those pa-
rameters, obtaining an 80 % power with a statistical sig-
nificance threshold set at p = 0.05 would require each
treatment arm to recruit between 21 (if the primary out-
come in the placebo group is met in 41 % of subjects)
and 65 subjects (if the primary outcome in the placebo
group is met in 23 % of subjects). The initial recruitment
goal will, therefore, be of 65 subjects per group, for a
total of 130 analyzed patients. With two recruiting cen-
ters, this goal could be achieved within 2.5 years if more
than 40 % of screened patients are eligible and consent
to participate.
This power analysis is based on a number of assump-
tions, including the incidence of the primary outcome, the
size of the treatment effect, the proportion of patients
undergoing planned surgical evacuation and the rate of
change from planned conservative to surgical management
(which leads to a failure of meeting the primary outcome).
This can significantly impact the power of the study. Since
100 % of the 22 cases published achieved complete CSDH
resolution [15, 16], powering for an incidence of primary
outcome of 46–82 % in the treatment arm (odds ratio of 2)
seems reasonable. A lower odds ratio could still be clinically
significant given the reported safety of TXA, although de-
tecting it would require a substantially larger cohort (225
subjects per group for a 1.5 odds ratio with a 23 % rate of
primary outcome in the placebo group). To verify these as-
sumptions, an interim power analysis will be performed
after follow-up data is available for the 65th subject and
using the study’s real primary outcome incidence. Target
sample size will be adjusted if this analysis suggests that the
power required to assess effectiveness could be reached
with available or minimal extension of funding. However,
while TRACS is designed to provide preliminary efficacy
data, the main objective is to provide the feasibility, safety
and incidence data required to plan a larger definitive phase
III trial. Therefore, powering for effectiveness is not strictly
required.
Ethics, consent and permissions
Study explanation to potential subjects will be performed
by research personnel independent from the treating physi-
cians. Consent will be obtained from the patient directly
whenever possible. However, it is expected that a significant
proportion of patients in the target population will be un-
able to give informed consent because of confusion or
speech impairment caused by their condition. In such
cases, consent will be obtained from a legal representative
or the patient’s most significant relative. Consent to remain
in the study will be obtained from the subject as soon as
competency to consent is recovered. This process is in ac-
cordance with the World Medical Association’s Declaration
of Helsinki [19]. The TRACS trial has received local Institu-
tional Review Board (IRB) (Comité d’éthique de la
recherche du CR-CHUS) approval as well as approval from
Health Canada. The French and English consent forms are
available as Additional files 3 and 4.
Stopping guidelines
The safety profile of TXA is well-established and the
probability of harm resulting from study participation
is low. Because TRACS is a small study, no predefined
stopping guidelines have been included in the proto-
col. All complications will be reviewed by the principal
investigator as they occur and by the safety monitoring
committee at a planned meeting scheduled after
follow-up data is available for the 65th subject. Should
any concern arise, the data will be submitted for evalu-
ation by the IRB and further enrollment stopped until
a decision is made.
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Randomization, blinding and unblinding
Upon giving informed consent, subjects will be random-
ized by the recruiting center’s central pharmacy to one
of two groups: a group treated with TXA and a control
group treated with a placebo. Stratified block
randomization will be used with a block size of 4 and
the use of antiplatelet drugs within the last month and
recruiting center as covariates. The allocation sequence,
produced by an independent statistician, will be deter-
mined by assigning a random number to each subject
within a block (two taking placebo and two taking TXA)
and then sorting the subjects by number. Four tables of
128 allocations will be generated with Table A used for
patients not previously taking antiplatelet therapy and
Table B used for patients previously taking antiplatelet
therapy. Tables C and D will be similarly generated and
reserved for the second recruiting center. Subjects and
care providers will be blinded by the use of a placebo
tablet. In order to minimize cost, the placebo tablet will
not be perfectly identical to the TXA tablet and the
drugs will, therefore, be served in an opaque container
to further protect the allocation from the physician.
Blinding will be maintained throughout the trial period,
including during the interim analysis where patient’s
group assignation will be unmasked, but not the group’s
assignation to a specific treatment. After database lock
following the last follow-up of the last patient, planned
statistical analyses will be performed and conclusions
drawn and presented to the trial steering committee
prior to unblinding of the groups’ allocation.
There should be no need for unblinding during the
treatment phase. If, for any patient, an adverse event oc-
curs such as a thrombosis, pseudo-nephrolithiasis or
suspected allergic reaction, the trial intervention should
be stopped for the affected patient and standard sup-
portive care given. Should the attending physician re-
quire unblinding, the coordination center’s pharmacy
can be contacted at any time.
Intervention
TRACS is divided into three phases: (1) the treatment
phase, (2) the post-treatment phase, and (3) the optional
surgical phase (see Fig. 1).
The treatment phase begins immediately after
randomization and involves the administration of daily
oral TXA or placebo. Planned procedures include blood
tests at 0 weeks, a set of questionnaires and cognitive
function tests at 0 and 10 weeks and serial CT scans
every 5 weeks. The first CT scan will be contrast-
enhanced to assess the degree of membrane
vascularization. Throughout the treatment phase and re-
gardless of treatment arm assignation, CSDH manage-
ment proceeds at the discretion of the attending
physician. This can include a conservative observation
Fig. 1 Intervention schedule. The TRACS trial is divided into three phases. The treatment phase is entered upon enrollment. The post-treatment
phase is entered upon complete radiological resolution of the chronic subdural hematoma (CSDH) on follow-up computed tomography (CT)
scans or after 20 weeks of treatment. The optional surgical phase is entered if the subject undergoes surgical CSDH evacuation
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period, a surgical evacuation or any procedure deemed
appropriate by the medical team. Resumption of prior
antiplatelet medications is not standardized but is docu-
mented. The treatment phase continues until complete
radiological resolution of the CSDH or for a maximum
of 20 weeks.
The post-treatment phase begins at the first CT scan
demonstrating complete radiological resolution of the
CSDH or after 20 weeks of treatment. It involves the
cessation of trial drug administration and a set of ques-
tionnaires, cognitive function tests and a CT scan to be
performed after 3 months following treatment cessation.
If a surgical evacuation is performed, the optional sur-
gical phase is entered and mandates sampling and ana-
lysis of the hematoma and its outer membrane, as
detailed in the Outcomes section. Surgical technique is
left to the discretion of the treating team. Timing of sur-
gery, use of drains and use of burr holes versus craniot-
omy will be recorded, but are not pre-specified.
Treatment adherence will be monitored by asking pa-
tients to return any remaining drug tablets at each clin-
ical visit and at the end of the study. The schedule of
enrollment, interventions, and assessments is summa-
rized in Fig. 1.
Dose selection
TXA has been used for many applications and the doses
studied vary widely. Loading doses of 2.5–100 mg/kg
and maintenance doses of 0.25–4 mg/kg/h have been re-
ported as safe and effective in surgical patients, although
total treatment duration in these studies was less than
12 h [20]. Approved dosing for menorrhagia is 1300 mg
three times daily for up to 5 days. Off-label, long-term
use of 500 mg/dose PO once or twice daily has been re-
ported for hereditary angioedema prophylaxis with some
patients treated safely for years [21].
CSDH is believed to result from a slow, occult bleed-
ing from the subdural hematoma membrane. The goal
of an antifibrinolytic therapy in this context is to correct
the coagulopathy within the hematoma so that throm-
bosis of the surrounding membrane can occur and be
followed by CSDH reabsorption. Because this process is
unlikely to take place within 12 h, the use of a long-
term, low-dose regimen might be favored. In the first
case report of TXA use for CSDH, a dose of 20 mg/kg/
48 h IV for 4 weeks, followed by 10 mg/kg/48 h PO for
4 weeks was administered [15]. For a 70-kg subject, this
would yield 700 mg IV daily for 4 weeks, followed by
350 mg PO daily for 4 weeks. For all the other reported
patients, a dose of 750 mg PO daily was used [16]. Be-
cause of the high effectiveness and absence of adverse
event in this series, the latter dose was chosen for the
TRACS trial.
TXA and placebo will be provided as tablets to be
taken orally. The drug can be administered through a
nasogastric tube if the patient is dysphagic.
Drug manufacture and supply of trial treatment
TXA and placebo drugs will be purchased on the open
market by the trial coordinating center pharmacy
(Centre de recherche du CHUS). The pharmacy will also
manage the blinding process and drug packaging. As
long as subjects are hospitalized, the drugs will be ad-
ministered by the ward nurses along with the patient’s
other medication. Upon discharge, remaining doses will
be packaged and given to the patient with detailed writ-
ten administration instructions. The initial trial drug ser-
vice will cover the first 10 weeks of treatment. If, at the
10-week follow-up, the control CT scan demonstrates
persistence of the CSDH, a second service of trial drugs
will be performed and the treatment will be continued
for a total of 20 weeks. Complete radiological resolution
of the CSDH on any CT scan, at any time during the
treatment phase, will end the trial intervention and trig-
ger the post-treatment phase. At treatment cessation,
remaining drug tablets will be collected be the trial phar-
macy and counted to monitor compliance.
Venous thrombosis prophylaxis
All hospitalized patients will undergo mandatory stand-
ard neurosurgical venous thrombosis prophylaxis con-
sisting of intermittent compression stockings plus 5,000
units of unfractionated heparin given subcutaneously
twice daily (or thrice if the patient weighs over 100 kg),
to be discontinued 12 h preoperatively and resumed
12 h after removal of all postoperative subdural drains.
Prophylaxis will be discontinued at hospital discharge.
Other treatments
TXA or placebo administered as part of the TRACS trial
is provided as an adjunct to the usual management of
CSDH. There is no need to modify or withhold any clin-
ically indicated treatment, including surgery, antiplatelet
therapy or prophylactic heparin administration.
Adverse events
The use of the trial’s regimen was not associated with
any complication in the only available study [16]. Other,
higher-dose TXA regimens have been proven safe and
effective for other indications [22, 23]. However, our
study population will likely be older than these earlier
studies and TRACS will specifically assess TXA safety in
the CSDH population. As such, adverse events will be
systematically monitored during hospital stay and at
each follow-up. Any event thought by the treating phys-
ician to be potentially related to TXA will be reported
within 48 h of detection using a standardized Adverse
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Event Report Form. Adverse events to be specifically
assessed at each follow-up include the incidence of deep
venous thrombosis, pulmonary embolism, transient ische-
mic attacks, stroke, pseudo-nephrolithiasis and subjective
changes in vision. Any other side effects reported by pa-
tients will also be documented. Adverse Event Reports will
be screened by each site’s principal investigator as soon as
they are produced. An independent safety monitoring com-
mittee will review all Adverse Event Reports, and analyze
the rates of TXA adverse events after follow-up data is
available for the 65th subject. As part of the interim ana-
lysis, the safety monitoring committee will produce a report
to be reviewed by the trial steering committee and might
request a trial review by the IRB should any concern arise.
Group allocation unblinding will be performed if a highly
statistically significant (p <0.001) difference in the rate of
adverse events is identified.
Adverse events will be reported using the classification
of the Medical Dictionary for Regulatory Activities, ver-
sion 19.0.
Measures of outcome
The primary outcome is the rate of complete CSDH
radiological resolution (see definition in CSDH radio-
logical assessment section below) by 20 weeks without
intervening unplanned surgical procedure. The manage-
ment strategy chosen is documented at the time of
randomization as a categorical variable (no surgery
planned versus elective evacuation planned versus emer-
gent (cannot wait 24 h) evacuation planned). An un-
planned surgical procedure is any surgery performed in
addition to the management strategy documented at
randomization. Specifically:
 If the management strategy chosen by the attending
physician within the first 24 hours of presentation
included a surgical evacuation of the CSDH, the
primary outcome is met if a control CT scan by
20 weeks demonstrates complete radiological
resolution of the CSDH.
○ If a second surgical procedure is required, the
subject is considered to have failed CSDH treatment
and the primary outcome is not met, even if the
CSDH has completely resolved by 20 weeks
○ If a surgical procedure is never performed, the
primary outcome is met if a control CT scan by
20 weeks demonstrates complete radiological
resolution of the CSDH
 If the management strategy chosen by the
attending physician within the first 24 hours of
presentation consisted of expectant management,
the primary outcome is met if a control CT scan
by 20 weeks demonstrates complete radiological
resolution of the CSDH.
○ If a surgical procedure is performed, the subject
is considered to have failed CSDH treatment and
the primary outcome is not met, even if the
CSDH has completely resolved by 20 weeks
For patients presenting with bilateral hematomas, only
the largest hematoma at presentation will be considered
for the primary outcome analysis.
The secondary outcomes are:
 CSDH volume at 20 weeks
 Incidence of surgical evacuation procedures
 Incidence of symptomatic and asymptomatic CSDH
recurrence at 3 months following complete
radiological resolution
 Cognitive functions at 10 weeks following
randomization and at 3 months following the end of
treatment as assessed by the Mini-Mental State
Examination (MMSE)
 Functional autonomy at 10 weeks following
randomization and at 3 months following the end of
treatment as assessed by the modified Barthel Index
(mBI) and Glasgow Outcome Scale Extended
(GOSE)
 Quality of life at 10 weeks following randomization
and at 3 months following the end of treatment as
assessed by the EuroQol five dimensions, five levels
health survey (EQ-5D-5L) questionnaire
 Length of initial hospital stay
 Number of rehospitalization
 Incidence of complications
Additional variables will be collected to allow planned
subgroup analyses of the primary outcome, secondary
outcomes and response to TXA when stratifying patients
by:
 Conservatively versus surgically managed patients
 Level of CSDH membrane contrast-enhancement on
the initial CT scan
 Level of CSDH membrane vascularization on
histopathological analysis
 Evidence of coagulopathy in the CSDH
The primary analysis will be performed and reported
on an intention-to-treat basis. As-treated analyses and
hematoma-level analyses (for patients with bilateral
CSDH) will also be performed and compared to the
intention-to-treat results.
CSDH radiological assessment
CSDH will be assessed by serial CT scanning. Volume will
be measured by segmentation of the CSDH using Osirix
6.5 (Pixmeo, Geneva, Switzerland). Contrast enhancement
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of the membrane will be assessed on injected sequences
by volume measurement and reported as the volume/vol-
ume percentage of contrast enhancement relative to the
total CSDH volume. Radiological resolution of the CSDH
is defined as the absence of a measurable subdural collec-
tion discernable from cerebrospinal fluid (CSF) on the 3-
mm sliced axial reconstructions of a non-enhanced iso-
tropic CT scan. Recurrence is defined as the apparition of
a new CSDH after radiological resolution of a prior known
CSDH in the same location. Progression is defined as a
more than 10 % increase in CSDH volume.
Radiological resolution during the treatment phase will
be assessed by local investigators who will review the CT
scans as they are performed and trigger the post-treatment
phase upon resolution or at 20 weeks. All local investigators
will undergo a standardized training in CSDH radiological
resolution assessment by the study radiologist prior to
subject enrollment at their center. After study completion,
all CT scans will be centrally reviewed by an independent,
blinded radiologist who will perform the volumetric ana-
lyses and determine the official CSDH resolution and recur-
rence status for outcome analyses.
Cognitive functions assessment
Cognitive functions will be assessed using the Mini-
Mental State Examination (MMSE), a validated and
widely used test [24].
Functional autonomy assessment
Functional autonomy will be assessed using a 10-item
questionnaire: the Modified Barthel Index of Activities
of Daily Living (mBI) [25]. This tool has been used in
more than 2500 studies and is the most commonly used
functional autonomy scale in the elderly [26]. The Glas-
gow Outcome Scale Extended (GOSE) will also be used
at the last follow-up to measure gross functional auton-
omy. It is the most frequent outcome measure in neuro-
surgical trials, although less sensitive than the mBI for
highly functional individuals.
Quality of life assessment
Quality of life (QOL) will be assessed using the EQ-5D-
5L questionnaire, a validated QOL tool and standard test
for cost-effectiveness and health utility analyses [27].
Hematoma analysis
Patients enrolled in the trial and undergoing surgical
evacuation of their CSDH provide an opportunity for
further analysis of CSDH pathophysiology. Immediately
after trepanation, the CSDH and its outer membrane
will be sampled. Levels of glucose, proteins, osmolarity,
prothrombin time (PT), activated partial thromboplastin
time (aPTT), fibrinogen, D-dimers and the platelet count
will be measured in the hematoma liquid. A measure of
membrane vascularization will be reported as assessed
by standard hematoxylin and eosin staining and immu-
nohistochemical labeling. Membrane analysis will be
performed by a single, blinded pathologist at the coord-
inating center. For better reproducibility, all membranes
will be analyzed simultaneously once patient recruitment
has stopped and the last follow-up is completed. Sam-
pling of the CSDH will not affect the surgical procedure
itself and no tissue will be banked for future use once
the trial analyses have been performed.
Data collection and management
All data will be collected by the recruiting center’s re-
search personnel. Paper data collection forms will be
used (see Additional file 5) when questioning patients
and then transcribed in a secure online database with
range checks for data values. At the time of analysis, all
outliers in the electronic data will be double-checked on
the paper questionnaires to rule out errors in data entry.
All data will be conserved for 25 years after the end of
the study. Data will be collected for all enrolled patients
even if the intervention is discontinued. Investigators,
the trial steering committee and the safety monitoring
committee will have access to the final dataset.
Participant-level data and statistical code will be made
available upon request for external review, substudies or
meta-analysis purposes.
Analysis
The statistical analysis plan and interim analysis plan are
provided as Additional file 2 (as part of the detailed
protocol). After database lock, inclusion and exclusion
criteria (including imaging and clinical data) for all en-
rolled patients will be validated by an independent re-
viewer. Patients randomized despite not being eligible
will be excluded from the primary analysis. Missing data
will be handled by means of multiple imputation ana-
lyses. Baseline characteristics of each treatment arm will
be tested for similarity using Student’s t test or the
Mann-Whitney U test depending on distribution nor-
mality. Tested characteristics will include age, sex, alco-
hol consumption, smoking status, previous history of
CSDH, use of antiplatelet medication, ACE inhibitors or
glucocorticoids, previous lumbar puncture or neurosur-
gical procedure, recent head trauma, baseline question-
naire scores, coagulation parameters and radiological
parameters. Primary and secondary outcomes analyses
will be performed and reported on an intention-to-treat
basis. Complementary as-treated and hematoma-level
analyses will also be provided. Treatment effect on
primary and secondary outcomes will be tested using the
appropriate statistical tests with reporting of the effect size
and a measure of precision. Briefly, the primary outcome
will be assessed using Fisher’s exact test. Linear mixed
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models will be used to test the impact of treatment arm on
CSDH volume and the various questionnaire scores. GOSE
score, hospitalization length and number of readmissions
will be tested using Student’s t test or the Mann-Whitney U
test. Other secondary outcomes will be tested using Fisher’s
exact test. Statistical significance will be defined as p <0.05.
Risk factors for primary outcome failure will be ex-
plored using logistic regression analyses. Potential risk
factors to be tested include age, alcohol consumption,
smoking, previous history of CSDH, use of antiplatelet
medication, ACE inhibitors or glucocorticoids, previous
neurosurgical procedure, chronic renal failure, brain
atrophy, convexity CSDH, loculated CSDH, enhancing
CSDH membranes, high membrane vascularization and
low fibrinogen level in the CSDH fluid. Subgroup ana-
lyses of the primary outcome will also be performed for
conservatively managed patients and surgically managed
patients.
Results will be published in peer-reviewed journals
and reported in the ClinicalTrial.gov result database.
Administrative data
Protocol development
The protocol was developed by and following the in-
put of:
 Dr David Mathieu MD, Department of Surgery
(Neurosurgery), principal investigator
 Dr Christian Iorio-Morin MD PhD, Department of
Surgery (Neurosurgery)
 Dr Jocelyn Blanchard MD, Department of Surgery
(Neurosurgery)
 Dr Jean-François Castilloux MD, Department of
Medicine (Hematology)
 Dr Jean Chénard MD, Department of Diagnostic
Radiology
 Dr Ana-Maria Crous Tsanaclis MD, Department of
Pathology
 Dr Maxime Richer MD PhD, Department of
Pathology
 Dr Marie-Pierre Garant PhD, statistician
No patient was involved in the development of the
study protocol.
Trial steering committee
The trial steering committee will oversee the progress of
the trial, review the safety data, review the Adverse
Events Reports as they become available and provide ad-
vice regarding trial extension and funding after the
power calculations are performed using the interim ana-
lysis data. The trial steering committee will consist of:
 Dr David Mathieu MD, Department of Surgery
(Neurosurgery), principal investigator
 Dr Christian Iorio-Morin MD PhD, Department of
Surgery (Neurosurgery)
 Dr Jocelyn Blanchard MD, Department of Surgery
(Neurosurgery)
Safety monitoring committee
The safety monitoring committee will analyze the safety
data and all Adverse Events Reports available at the in-
terim analysis. They will provide advice to the trial steer-
ing committee for protocol improvement and might
request IRB reevaluation should significant safety con-
cerns arise from the interim analysis report. The safety
monitoring committee will consist of:
 Dr François Lamontagne MD MSc, Department of
Medicine (Critical Care)
 Dr Jean-François Castilloux MD, Department of
Medicine (Hematology)
 Dr Nicolas Dea MD MSc, Department of Surgery
(Neurosurgery)
 Dr David Fortin MD MSc, Department of Surgery
(Neurosurgery)
Financial support
Funding for the TRACS trial has been provided by:
 Fond de recherche du Québec – Santé
 Centre de recherche du CHUS
 Department of Surgery, University of Sherbrooke
 Fondation Neuro-Trauma Marie-Robert
Additional funding sources are being solicited. There
is neither funding nor support provided by the pharma-
ceutical industry.
This trial will not generate any intellectual property
for the sponsor or any participating party. The funders
did not participate at any point in the design of the
study and will have no role in data collection, manage-
ment, analysis, interpretation and reporting.
Discussion
CSDH is a frequent and morbid condition. A better un-
derstanding of the underlying pathophysiological pro-
cesses will support direct targeting of dysregulated
elements of coagulation cascades that are thought to be
responsible for CSDH growth. TXA is a safe and widely
used inhibitor of fibrinolysis. Its effective use as a med-
ical treatment for CSDH has been reported for 22 pa-
tients. While these results are promising, their
retrospective and uncontrolled nature does not allow
any conclusion regarding TXA effectiveness in CSDH to
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be drawn. TRACS will be the first prospective trial of
TXA in CSDH.
Safety
TRACS’ protocol requires discontinuation of TXA ad-
ministration at the first CT scan demonstrating complete
CSDH radiological resolution rather than at a fixed 20-
week time point. This design decision will result in vari-
able treatment duration and time of primary outcome
assessment within the cohort. We anticipate that our pa-
tient population will be significantly older and at higher
risk for complications than most other studies of TXA.
While the low TXA dose used in TRACS will hopefully
increase the safety of the intervention, the risk of
thromboembolic events will likely be proportional to
treatment duration. Therefore, because the goal of TXA
treatment is resolution of the CSDH, we believe this
variable treatment duration paradigm will maximize the
safety of the intervention by allowing treatment to be
discontinued in patients who have responded and for
whom no additional benefit is expected, while allowing a
longer course of treatment to non-responders.
Consequently, total follow-up will also be variable
since the last follow-up, scheduled 3 months following
treatment cessation, will depend on the time at which
CSDH resolution occurred. Because the goal of this
post-treatment assessment is to investigate recurrence
relative to the demonstration of complete resolution and
treatment cessation (as opposed to initial CSDH diagno-
sis and treatment start), we do not believe this design
will introduce any significant bias.
Expected impact
The TRACS trial will provide safety and incidence data, as
well as effect size estimation to inform the design of a lar-
ger, definitive trial. Depending on the resulting power cal-
culations, TRACS itself could be sufficiently powered to
provide reliable evidence as to whether TXA can increase
the rate of CSDH resolution following conservative man-
agement, lower the number of required surgical proce-
dures and decrease the rate of CSDH recurrence following
surgical evacuation. Exploratory analyses will investigate
the impact of CSDH presence and resolution on QOL and
cognitive function. While patients with no pain, motor
deficit or marked cognitive impairment are often consid-
ered “asymptomatic,” these analyses might identify subtle
yet clinically meaningful deficits that might benefit from a
minimally-invasive treatment. Planned subgroup analyses
will try to identify risk factors for CSDH recurrence and
TXA failure with particular focus on prior use of anti-
platelet medication, poorly-vascularized CSDH mem-
branes and low fibrinogen levels within the CSDH fluid.
CSDH sampling in the surgical patients and subsequent
comparison of biochemical and immunohistological data
to clinical outcome will further enhance our understand-
ing of the pathophysiology of CSDH with the goal of pre-
dicting TXA response in individual patients. If the trial
hypothesis is confirmed, it could help position TXA as a
new non-invasive treatment modality for CSDH.
Trial status
Patient enrollment began at the coordinating center in
late October 2015. At the time of submission (March
2016), nine patients had been enrolled. Enrollment at
the second site has not yet begun. Any change to the
trial protocol will be communicated to relevant parties
by the principal investigator and mentioned in the re-
sults manuscript.
Consent to publish
Consent to publish anonymized, individual patient data
will be obtained as part of the general consent for study
participation.
Additional files
Additional file 1: SPIRIT checklist. (DOC 122 kb)
Additional file 2: Protocol (original French version). (PDF 3571 kb)
Additional file 3: Consent form (original French version). (PDF 253 kb)
Additional file 4: Consent form (English translation). (PDF 324 kb)
Additional file 5: Data collection forms (original French version).
(PDF 334 kb)
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